Premium
European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology
Author(s) -
Enk A.H.,
Hadaschik E.N.,
Eming R.,
Fierlbeck G.,
French L.E.,
Girolomoni G.,
Hertl M.,
Jolles S.,
Karpati S.,
Steinbrink K.,
Stingl G.,
VolcPlatzer B.,
Zillikens D.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13725
Subject(s) - medicine , toxic epidermal necrolysis , intravenous immunoglobulins , dermatology , dermatological diseases , intensive care medicine , clinical trial , clinical practice , antibody , immunology , family medicine , pathology
Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis ( TEN ) with high‐dose intravenous immunoglobulin ( IVI g) is a well‐established procedure in dermatology. As treatment with IVI g is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence‐based medicine. Owing to the rarity of the indications for the use of IVI g, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVI g treatment also limit its first‐line use, the first clinical guidelines on its use in dermatological conditions were established in 2008 and renewed in 2011. Materials and methods The European guidelines presented here were prepared by a panel of experts nominated by the EDF and the EADV . The guidelines were developed to update the indications for treatment currently considered as effective and to summarize the evidence base for the use of IVI g in dermatological autoimmune diseases and TEN . Results and conclusion The current guidelines represent consensual expert opinions and definitions on the use of IVI g reflecting current published evidence and are intended to serve as a decision‐making tool for the use of IVI g in dermatological diseases.